©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2022; 14(1): 75-89
Published online Jan 15, 2022. doi: 10.4251/wjgo.v14.i1.75
Published online Jan 15, 2022. doi: 10.4251/wjgo.v14.i1.75
Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers
Hui-Yan Sun, Song-Tao Du, Ya-Yun Li, Guang-Tong Deng, Fu-Rong Zeng, Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Hui-Yan Sun, Fu-Rong Zeng, Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Hui-Yan Sun, Song-Tao Du, Ya-Yun Li, Guang-Tong Deng, Fu-Rong Zeng, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Hui-Yan Sun, Song-Tao Du, Ya-Yun Li, Guang-Tong Deng, Fu-Rong Zeng, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Song-Tao Du, Department of Colorectal Surgical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang Province, China
Author contributions: Zeng FR, Deng GT and Sun HY designed the study; Sun HY and Deng GT wrote the manuscript; Du ST, Li YY helped to revise the manuscript; all the authors supported the study.
Supported by Fellowship of the China Postdoctoral Science Foundation , No. 2020M682594, and No. 2021T140748.
Conflict-of-interest statement: No conflict of interest.
Corresponding author: Fu-Rong Zeng, MD, Doctor, Department of Oncology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha 410008, Hunan Province, China. zengflorachn@hotmail.com
Received: March 17, 2021
Peer-review started: March 17, 2021
First decision: July 27, 2021
Revised: August 11, 2021
Accepted: November 30, 2021
Article in press: November 30, 2021
Published online: January 15, 2022
Processing time: 299 Days and 20.4 Hours
Peer-review started: March 17, 2021
First decision: July 27, 2021
Revised: August 11, 2021
Accepted: November 30, 2021
Article in press: November 30, 2021
Published online: January 15, 2022
Processing time: 299 Days and 20.4 Hours
Core Tip
Core Tip: Bromodomain and extra-terminal (BET) inhibitors, as promising targeted agents, emerge as a new therapeutic avenue for gastrointestinal (GI) cancers. Based on preclinical evidence, BET inhibitors, alone or in combination with other therapies, were effective to suppress the progression of GI cancers.